INTRODUCTION
The tumour suppressor protein p53 is negatively regulated by components of the ubiquitin-dependent degradation machinery that direct p53 to the proteasome [1] and is positively regulated by protein kinase cascades that assemble p53 into transcription complexes [2] . The Mdm2 (murine double minute 2) protein plays multiple regulatory roles in attenuating the function of p53 as a transcription factor including transrepression of p53-dependent gene expression [3] . However, it is the activity of Mdm2 as an E3-ubiquitin ligase that has excited the most interest in recent years and which may explain the oncogenicity of Mdm2 in cells that are null for p53 [4] . Mdm2-catalysed ubiquitination of p53 leads to proteasomal degradation and thereby controls the steady-state levels of the p53 protein in cycling cells. However, the biochemical mechanism describing how the core E1-E2-E3 system recognizes and ubiquitinates p53 is not fully defined.
The binding interface between Mdm2 and p53 is complex and highly regulated. The transactivation domain of p53 (BOX-I) binds to a hydrophobic cleft in the N-terminus of Mdm2 [5] , leading to transrepression of p53 activity [3] . Occupation of the Mdm2 hydrophobic pocket by the transactivation domain of p53 (BOX-I) generates conformational changes that favour further interactions between the acid domain of Mdm2 and a surface in the core of p53 which encompasses the S9-10 linker and BOX-V motif [6] [7] [8] . It is this complex interface within the core DNAbinding domain of p53 that comprises the ubiquitination signal. Mutations in p53 that expose the Mdm2-binding site in the DNAbinding domain lead to enhanced ubiquitination in tumour cell lines [6, 7] and a striking destabilization of the mutant p53 protein in murine transgenes [9] .
The identification and molecular characterization of novel substrates that would provide further insights into the structure, regulation and functions of Mdm2 is an important goal for unravelling Mdm2-mediated pathways in human diseases such as cancer. However, a paucity of studies that define substrate-ligase interfaces has, to date, limited the structure-function analysis of Mdm2. As one of the fundamental aspects of the Mdm2-p53 ubiquitination reaction is that Mdm2 interacts at two distinct interfaces, we have used search engines that can identify homologous linear interaction motifs that match the two Mdm2-docking sites in p53. Here, we describe one such protein identified as IRF-2 [IFN (interferon) regulatory factor-2], an IFN-regulated transcription factor [10] . This protein has two peptide motifs with highly significant homology with the two Mdm2-docking sites in p53; indeed these two binding sites are required for Mdm2-mediated ubiquitination of IRF-2, highlighting a fundamental ability of Mdm2 to recognize a substrate via a dual-site docking mechanism. This defines a novel substrate for Mdm2 that provides an independent tool with which to probe Mdm2 structure-function relationships as an E3-ubiquitin ligase.
MATERIALS AND METHODS

Antibodies, plasmids and peptides
pcDNA/IRF-2 was constructed from a HindIII/XbaI fragment containing human IRF-2 ligated into pcDNA3. and GST (glutathione transferase)-IRF-2 was expressed from a pDEST15 vector coding for full-length human IRF-2, and GFP (green fluorescent protein)-IRF-2 contained full-length IRF-2 in pDEST53. FK1 and FK2 were supplied by BioMol International; anti-IRF-2 (C19) polyclonal serum was from Santa Cruz Biotechnology; the monoclonal antibodies 4B2 and 2A10 were used to detect Mdm2. Biotin-labelled peptides were from Mimitopes.
Cell culture, immunoprecipitation and immunoblots
H1299 cells were maintained in RPMI 1640 (Invitrogen) plus 5 % (v/v) FCS (foetal calf serum) and 1 % penicillin/streptomycin at 37
• C and 5% CO 2 , whereas A375 cells grow in DMEM (Dulbecco's modified Eagle's medium) plus 5 % FCS at 37
• C and 10 % CO 2 . The cells were transfected at 80 % confluency using Lipofectamine TM 2000 (Invitrogen). Immunoblots were carried out as previously described [11] . Immunoprecipitations were performed using published methods [12] .
Ubiquitination assays and ELISA
Cell-based ubiquitination assays were carried out as previously described [7] . The in vitro ubiquitination reactions contained 25 mM Hepes (pH 8.0), 10 mM MgCl 2 , 4 mM ATP, 0.5 mM DTT (dithiothreitol), 0.05 % Triton X-100, 0.25 mM benzamidine, 10 mM phosphocreatine, 3.5 units/ml creatine kinase, ubiquitin or His-tagged ubiquitin (2 μg), and E1 (100 nM), E2 (1 μM) and GST-or His-tagged IRF-2 protein (100 ng). Reactions were started using purified Mdm2 (50 ng), incubated for 20 min at 30
• C and analysed using 4-12 % NuPAGE gels in a Mops buffer system (Invitrogen) followed by immunoblotting. For the peptide ELISA, biotin-labelled peptides were captured on to streptavidin-coated plates as detailed in the Figure legends. Non-reactive sites were blocked using PBS containing 3 % (w/v) BSA and the wells were incubated with empirically determined amounts of Mdm2 protein (in the presence or absence of added ligand) in PBS + 0.1 % BSA for 1 h at room temperature (25 • C). The plates were washed extensively with PBS + 0.1 % Tween 20, and Mdm2 binding was detected using 2A10 and ECL (enhanced chemiluminescence). The protein ELISAs were performed by coating white 96-well plates with the protein of interest (as detailed in the Figure legends) in 0.1 M sodium borate. Non-reactive sites were blocked using PBS containing 3 % BSA and the wells were incubated with empirically determined amounts of Mdm2 or IRF-2 protein in PBS + 0.1 % BSA for 1 h at room temperature. Binding was detected using the appropriate primary antibodies by following previously published methods [7] .
Protein preparation
Mdm2 was expressed and purified as previously described [13] . GST-IRF-2 and His-IRF-2 were purified on glutathioneSepharose and nickel-agarose respectively by following the manufacturer's instructions. Untagged IRF-2 was expressed from pkBluescript/IRF-2-transformed Escherichia coli BL21 after treatment with 0.5 mM IPTG for 2 h at room temperature. After harvesting, the bacteria were resuspended in an equal volume of 50 mM Hepes (pH 8.0) containing 10 % sucrose and frozen in liquid nitrogen. The cells were thawed in an ice-water bath in the presence of 0.25 M KCl, 2 mM DTT, 0.5 mg/ml lysozyme and 400 μg/ml Pefabloc (final concentrations), and incubated at 4
• C for 30 min before centrifugation at 10 000 g for 15 min.
The supernatant was removed and diluted to 10 mg/ml total protein using column buffer (50 mM Hepes, pH 7.6, containing 10 % glycerol, 0.1 mM EDTA, 2 mM DTT, 0.1 % Triton X-100, 400 μg/ml Pefabloc and 1 mM benzamidine) and applied to a heparin-Poros column equilibrated in column buffer plus 100 mM NaCl. The column was washed with column buffer plus 100 mM NaCl and eluted with a linear gradient of 0.1-1.0 M NaCl. Fractions containing IRF-2 protein, as determined using immunoblots, were pooled, concentrated to > 1 mg/ml, divided into aliquots and frozen in liquid nitrogen.
RESULTS
Complex formation between IRF-2 and Mdm2
Recent studies have highlighted the complex nature of the binding interface between Mdm2 and its E3-ubiquitin ligase substrate p53 [6] [7] [8] . These studies suggest that the key 'signal' for p53 ubiquitination is binding of the Mdm2 acid domain to a complex ubiquitination signal in the core DNA-binding domain of p53 which encompasses its BOX-V/S9-10 linker region [6, 7] . The relatively weak interaction between the Mdm2 acid domain and p53-BOX-V is promoted by a higher affinity interaction between the hydrophobic pocket of Mdm2 and the transactivation domain (BOX-I domain) of p53. In order to identify Mdm2 substrates that may provide further support for the role of the acid domain in Mdm2-mediated ubiquitination of target substrates, we have used a bioinformatics approach. Using the Mdm2-interacting motifs of p53 to screen for open reading frames with homology to the BOX-I and/or the BOX-V domains of p53 ( Figure 1A ), a number of putative Mdm2-binding proteins were identified [6] ; among these was the transcription factor IRF-2. IRF-2 was chosen for further analysis as it had regions of homology with both the BOX-I and BOX-V domains. We first established whether IRF-2 and Mdm2 could form a complex in cells. When IRF-2 and Mdm2 were co-expressed in A375 cells and immunocomplexes captured using an anti-IRF-2 IgG, Mdm2 protein was co-precipitated, providing evidence that these two proteins are involved in interactions in a complex cellular background ( Figure 1B , lane 5). Consistent with the ability of Mdm2 to precipitate with IRF-2 ( Figure 1B ), the two proteins co-localized in the cell nucleus ( Figure 1C ) when GFP-IRF-2 was transfected into H1299 cells together with untagged Mdm2.
In order to establish whether Mdm2 and IRF-2 were able to bind directly or whether additional factors were required, the two human proteins were purified from an E. coli expression system and analysed using an ELISA format. A titration of purified Mdm2 ( Figure 1D , upper panel) or IRF-2 ( Figure 1D , lower panel) was captured on to the solid phase and incubated with IRF-2 or Mdm2 protein in the soluble phase respectively; binding was then detected using an appropriate primary antibody. The data show that Mdm2 and IRF-2 can interact directly in the absence of additional cellular factors.
Mdm2-dependent ubiquitination of IRF-2 in vitro and in cells
Using a well-characterized assay [14] , which measures the conjugation of His-ubiquitin to target proteins, we examined whether IRF-2 was a substrate for Mdm2 E3-ligase activity in cells ( Figure 2A ). Immunoblots were used to analyse ubiquitinconjugated proteins from crude cell lysates captured on Niagarose after the co-expression of IRF-2 and His-ubiquitin (Figure 2A) . In this assay, the presence of IRF-2 in the Ni-agarose pulldown was dependent on the presence of His-ubiquitin and no background IRF-2 binding was detected in its absence (Figure 2A) . When Mdm2 was co-expressed with IRF-2 and His-ubiquitin, a discrete banding pattern of ubiquitinated IRF-2 protein forms was detected (Figure 2A , lane 5 versus lane 4). There was some background IRF-2 modification in the presence of Hisubiquitin alone, which could be explained by endogenous Mdm2 or other IRF-2-directed E3-ligases. When wild-type Mdm2 was replaced by a RING (really interesting new gene) finger domain mutant (Mdm2/C464A) that loses the ability to ubiquitinate p53 [15] , no increase in ubiquitinated IRF-2 was seen over background ( Figure 2A , lane 9 versus lane 8).
We next wished to establish whether an in vitro assay could be used to measure the ubiquitination of IRF-2 by Mdm2 as this would permit quantitative analysis to be carried out using The results shown are representative of at least five separate experiments. (B) GST-IRF-2 (0.1 μg) was incubated with E1 (100 nM) and E2 (1 μM) in the presence or absence of ubiquitin (2 μM) and Mdm2 (50 ng) for 15, 30 and 45 min. Ubiquitination of IRF-2 was analysed by immunoblots that were developed using C19. (C) GST-IRF-2 (0.1 μg) was incubated for 20 min with E1 (100 nM), E2 (1 μM), ubiquitin (2 μM) and increasing amounts of Mdm2 (5-50 μg). Ubiquitination was detected by immunoblots that were developed with C19. mutant proteins. When purified full-length Mdm2 was incubated with purified GST-IRF-2 (similar results were obtained with His-IRF-2; results not shown) in the presence of an E1-activating enzyme, an E2-conjugating enzyme (UbcH5), ubiquitin and an ATP regeneration system, IRF-2 modification was dependent on the presence of both ubiquitin and Mdm2. The reaction proceeded in a time-and [Mdm2]-dependent manner ( Figures 2B and 2C) , demonstrating that Mdm2 can act as an E3-ubiquitin ligase for IRF-2 in this minimal system.
Previous studies have suggested that Mdm2 can mediate multiple monoubiquitination of p53 [15a] , although it is less clear whether Mdm2 alone is sufficient to catalyse polyubiquitination of its substrates or whether polyubiquitination requires additional cellular factors. In order to determine whether Mdm2-mediated ubiquitination of IRF-2 represented mono-or poly-ubiquitination, we used two monoclonal antibodies: FK2, which recognizes both mono-and poly-ubiquitin-modified substrates, and FK1, which only binds to polyubiquitinated substrates. When these antibodies were used to probe IRF-2 ubiquitination assays, FK2 picked up a discrete pattern of bands only when ubiquitinated forms of IRF-2 were present ( Figure 3A , lane 5 versus lane 6). In addition, both FK1 and FK2 detected high-molecular-mass products; however, these were seen in both the absence and presence of IRF-2 ( Figure 3A, lanes 5, 6, 8 and 9 ). As the high-molecular-mass products were dependent on the presence of Mdm2, they most likely represent Mdm2 auto-polyubiquitination. In order to confirm that Mdm2 was monoubiquitinating rather than polyubiquitinating IRF-2, we asked whether Mdm2 could catalyse the attachment of Lys 48 -linked ubiquitin chains to IRF-2. When a mutant form of ubiquitin was used where Lys 48 had been substituted with arginine (K48R), it had no effect on the ability of Mdm2 to ubiquitinate IRF-2; in fact, K48R-ubiquitin appeared to be conjugated more efficiently to IRF-2 than wild-type ubiquitin ( Figure 4B, lane 4 versus lane 2) .
Experiments presented in this section suggest that Mdm2-mediated ubiquitination of IRF-2 is primarily at the level of multimonoubiquitination, suggesting that polyubiquitination would require additional cellular factors.
Structural requirements for Mdm2-mediated ubiquitination of IRF-2
Although the RING domain of Mdm2 by itself is sufficient to act as an E3-ubiquitin ligase (in co-operation with the E2 UbcH5; [16] ), specific recognition of p53 as an Mdm2 substrate requires a complex interaction between the two proteins. In order to determine whether the ubiquitination of IRF-2 by Mdm2 was specific, we firstly asked whether, like modification of p53, the ubiquitination reaction required both the hydrophobic pocket and the acid domain of Mdm2 to be present in addition to the RING. GST-Mdm2 wild-type and mutant proteins where either the acid domain ( Ac) or the hydrophobic pocket ( N) had been deleted were purified and used in the in vitro ubiquitination reaction. Although the specific activity of GST-Mdm2 wild-type is lower than untagged Mdm2 (results not shown), it is still able to ubiquitinate IRF-2 ( Figure 4A, lane 1) . However, consistent with the mechanism of p53 ubiquitination by Mdm2 [7] , neither Mdm2 Ac nor Mdm2 N is able to act as an E3-ligase for IRF-2 despite the fact that the RING domain was present. The results suggest that ubiquitination of IRF-2 by Mdm2 occurs in a specific manner that relies not only on Mdm2 E3-ligase activity but also on the efficient recognition of the substrate by determinants with the RING.
IRF-2 was originally identified by us as a potential Mdm2 substrate by virtue of its homology with the BOX-I and BOX-V/S9-10 Mdm2-binding sites on p53 ( Figure 1A ). To determine whether the p53 homologous regions of IRF-2 are required for Mdm2 ubiquitination, we made two IRF-2 mutant proteins ( Figure 4B ): IRF-2MI, where the BOX-I homology motif was mutated, and IRF-2MV, where the BOX-V homology motif was mutated. When the ability of Mdm2 to ubiquitinate the mutant proteins was compared with wild-type IRF-2, there was a significant impairment ( Figure 4C ). The results suggest that the interface between IRF-2 and Mdm2, similar to that of p53 and Mdm2, is complex and that at least two regions of IRF-2 must contact Mdm2 to signal efficient ubiquitination.
Mdm2 acid domain interacting ligands inhibit Mdm2-mediated ubiquitination of IRF-2
The results presented above suggest a role for both the acid domain and the hydrophobic pocket of Mdm2 in the specific recognition of IRF-2 as a substrate for its E3-ligase activity. To explore the relative significance of these two domains in the mechanism of Mdm2-mediated ubiquitination of IRF-2, we used peptides or low-molecular-mass compounds that can bind to either the hydrophobic pocket of Mdm2 or its acid domain ( Figure 5A ). Figure 5 (B) shows that hydrophobic pocket interacting molecules (BOX-I peptide; PPLSQETFSDLWKLLP and Nutlin [17, 18] ) do not affect the ability of Mdm2 to mediate ubiquitination of IRF-2, whereas Rb1 (DQIMMCSMYGICKVKNIDLK; [7] ), an acid domain interacting peptide, significantly reduces the ubiquitination of IRF-2. Further characterization revealed that Rb1 could fully inhibit IRF-2 ubiquitination at a concentration of 25 μM, whereas the hydrophobic pocket-binding ligand BOX-I had no inhibitory activity at this concentration. To further support the role of the acid domain in the mechanism of IRF-2 ubiquitin signal recognition, we demonstrated that a second acid domain interacting peptide, this time based on the BOX-V domain of p53 (RNSFEVRVCACPGRD; [7] ), could also inhibit IRF-2 ubiquitination albeit with an increased I 0.5 compared with Rb1.
The results presented here and in the previous section ( Figure 4 ) support a model where binding of the hydrophobic pocket of Mdm2 to either full-length p53 or the isolated BOX-I domain is needed to promote conformational changes in Mdm2 which favour binding of the acid domain to the p53 core. Thus BOX-I and Nutlin do not inhibit Mdm2-mediated ubiquitination, but mimic full-length p53 by generating conformational changes in the Mdm2 that favour its E3-ligase function [7] , whereas acid domain-binding peptides act as direct competitive inhibitors for binding to the ubiquitination signal in the core of p53.
Ligand-stimulated increases in Mdm2 activity are mediated by the acid domain
It has previously been suggested that Mdm2 interacting ligands such as the RNA mimetic poly-G stabilize Mdm2 in a conformation that favours binding to the BOX-V/S9-10 linker of p53 [6] , leading to the hypothesis that such ligands might regulate Mdm2 activity as an E3-ligase. As the acid domain of Mdm2 is responsible for binding to the BOX-V domain of p53, we reasoned that a gain in acid domain binding should result in increased Mdm2 E3-ligase activity. Using IRF-2 as a model substrate for Mdm2, we first asked whether poly-G affected Mdm2 and IRF-2 complex formation. When IRF-2 was immobilized on a microtitre plate and incubated with a fixed amount of Mdm2 that had been (A) His-IRF-2 (0.1 μg) was incubated with E1 (100 nM), E2 (1 μM) and ubiquitin (2 μM) in the presence of equal amounts of GST-Mdm2wt, GST-Mdm2 N or GST-Mdm2 Ac. IRF-2 was detected by immunoblotting using C19 antiserum, and Mdm2 was detected using 2A10. The results are representative of two experiments. (B) Schematic diagram of the mutants used in (C), where the underlined residues have been mutated to alanine. (C) GST-IRF-2, GST-IRF-2MI and GST-IRF-2MV were incubated with E1 (100 nM), E2 (1 μM) and ubiquitin (2 μM) with increasing amounts of Mdm2 (5-50 ng). Ubiquitination of wild-type and mutant IRF-2 was analysed by immunoblotting as above. The results are representative of at least three individual experiments. The samples were analysed on two separate gels run at the same time using the same apparatus.
pre-incubated with a titration of poly-G, low amounts of poly-G stimulated Mdm2 binding to IRF-2 ( Figure 6A ). In contrast, when Mdm2 is immobilized and IRF-2 is incubated with poly-G, no poly-G-dependent increase is detected ( Figure 6A, left panel) , presumably because immobilized Mdm2 cannot undergo poly-G-dependent conformational changes. This result also suggests that the poly-G is affecting Mdm2-binding activity rather than IRF-2 activity. In order to determine whether this gain in binding resulted in a gain in E3-ligase activity, Mdm2-dependent IRF-2 ubiquitination assays were set up in which ubiquitination of IRF-2 had not gone to completion. Poly-G was then titrated into the assay. At low amounts of poly-G, there was a significant stimulatory effect of the ligand on Mdm2 activity, whereas higher amounts of poly-G inhibited ubiquitination. Finally, in order to establish whether increases in Mdm3 E3-ligase activity observed in the presence of low amounts of poly-G ( Figure 6B ) were mediated through acid domain interactions with IRF-2, we determined whether the poly-G-stimulated increase could still be inhibited by the acid domain interacting peptide Rb1. Figure 6(C) shows that at a concentration of poly-G that gives robust induction of Mdm2-dependent IRF-2 ubiquitination, Rb1 is an efficient inhibitor that completely ablates Mdm2-mediated modification of IRF-2.
DISCUSSION
Progress in understanding the structure of Mdm2 as it relates to its function and regulation is an important goal for improving the design of drugs aiming to target the different activities of Mdm2 for therapeutic benefit [19] . One approach to further characterize key features of Mdm2 structure and regulation is to carry out comparative biochemistry on distinct protein substrates. However, such efforts have been hampered because, with the exception of p53, there is a paucity of Mdm2 substrates where direct binding has been demonstrated and coupled with fine mapping studies so that point mutations within the Mdm2 Evidence presented here and previously [7] suggests that Mdm2 substrates need to interact with both the hydrophobic pocket (Hy) and the acid domain (Ac) in order to be ubiquitinated ('I.'). Ligands that bind to the acid domain, but not the pocket, can inhibit ubiquitination, suggesting that the acid domain is primarily involved in recognition of the substrate's ubiquitination signal. We show that ligands such as RNA ('Ii.'), which have been reported to interact with the acid and/or RING domain (R) [27, 28] activate Mdm2-mediated ubiquitination, by favouring binding to the substrate's ubiquitination signal [6] . Thus RNA may stabilize the acid domain in a more favourable binding conformation.
interfaces can be made that show a direct link to ubiquitination. We have identified IRF-2 as a novel Mdm2 substrate and our characterization suggests that this protein can be used as a valuable tool to dissect further the complex mechanisms that exist to control Mdm2 activity as an E3-ligase [7, 20] . IRF-2 is the only validated protein apart from p53 that has a defined two-site mechanism driving its Mdm2-dependent ubiquitination. Thus the studies reported in the present study, using sequence homology within the p53 ubiquitination signal to identify novel Mdm2 substrates, support the idea that the Mdm2 E3-ligase-substrate interface is complex, encompassing multiple domains on the target substrate [7, 8, 21] .
A role for the acid domain of Mdm2 in its activity as an E3-ligase was first suggested by cell-based studies where delta acid domain Mdm2 mutant constructs were defective in their ability to ubiquitinate p53 [22, 23] . However, a direct role of the acid domain in recognition of p53's ubiquitination signal was not appreciated until recently [7] . Initial studies showed that point mutations within the S9-10 linker region of p53 formed a second docking site for Mdm2 on p53 which directly influenced the ability of Mdm2 to utilize p53 as an E3-ligase substrate [6] . This hypothesis was supported (i) by NMR studies, which demonstrated that the acid domain of Mdm2 could interact with a region from within the p53 core [8] , and (ii) by biochemical analysis, revealing an allosteric regulation of Mdm2 which favours binding of the acid domain to the BOX-V/S9-10 linker which then is sufficient to signal p53 ubiquitination [7] . Additional support for this model comes from a cell-based study showing that constructs containing the acid domain of Mdm2 but minus the hydrophobic pocket can still ubiquitinate p53 [24] . In the present study, we have used a bioinformatics approach to demonstrate that it is possible to identify proteins capable of binding to Mdm2 and acting as an E3-ligase substrate by using the p53 interaction as a template.
Consistent with the acid domain being involved in transient regulatory interactions, it has been shown to bind linear interaction motifs in E3-ligase substrates, such as p53 [7] and, in the present study, IRF-2 ( Figure 2 ). In addition, the acid domain binds to inhibitors of Mdm2-mediated ubiquitination such as ARF (alternative reading frame) [25] and the Rb1 peptide ( Figure 5 [7] ). Together with previous results [7, 24] , the present study therefore suggests that binding of a protein to the hydrophobic pocket of Mdm2 is not sufficient for it to act as a substrate, but that substrates like IRF-2 and p53 must also be able to form an interaction with the acid domain ( Figure 7 ). Conversely, proteins that interact only with the acid domain, for example ARF, are unlikely to be efficient substrates for Mdm2; furthermore, as in the case of ARF, they are more likely to act as Mdm2 E3-ligase inhibitors [26] . Strong support for the role of the acid domain in dictating Mdm2-specific E3-ligase function comes from the use of Mdm2/Mdm4 chimaeric proteins. Mdm4, a close relative of Mdm2, shares its overall domain structure, having an N-terminal hydrophobic pocket that can bind p53, an acidic region and a C-terminal C2H2C4 RING. However, Mdm4 does not appear to have intrinsic activity as a ligase for p53 [23, 27] and, although Mdm4 has a C2H2C4 RING, it is unclear whether this supports a ligase function [28, 29] . Of interest is the fact that although Mdm4 has an acidic central region, it bears little sequence homology with the acid domain of Mdm2. When chimaeric constructs were generated where the acidic domain of Mdm4 was substituted for that of Mdm2, the protein was not an effective E3-ligase for p53 although it was still capable of autoubiquitination and retained the highaffinity p53-binding site in its N-terminus [22, 23] . This supports our observations that peptides that bind to the acid domain inhibit its Mdm2 E3-ligase activity against specific substrates such as p53 [7] and IRF-2 ( Figure 5 ), whereas hydrophobic binding pockets have no inhibitory activity in the ubiquitination assay. Thus the acid domain of Mdm2 and its specificity for proteins such as p53 and IRF-2 with a conserved acid domainbinding motif are key to understanding Mdm2's biochemical mechanism.
The available structural information suggests that the isolated acid domain (amino acids 210-304) is disordered in solution and may use a fold-on-binding mechanism to interact with linear interaction motifs in its binding partners [30] . It has been proposed that binding may involve β-strand addition, presumably through β-sheet or β-zipper formation [31] . This fold-onbinding mechanism would presumably enhance the specificity of the acid domain and analysis of the binding consensus would therefore allow us to identify additional substrates for Mdm2, as we have done in the case of IRF-2. Results presented in the current study suggest that some Mdm2 interactions stabilize or promote recognition of the substrate's ubiquitination signal by the acid domain. Our previous studies have demonstrated that the interaction of RNA ligands such as poly-G with Mdm2 can generate conformational changes which favour binding of Mdm2 to the BOX-V/S9-10 linker region of p53 [6] . Here, we have extended these studies to show that poly-G stabilizes the interaction between IRF-2 and Mdm2. This gain of Mdm2-binding affinity is reflected by an increase in E3-ligase activity when poly-G is present at low concentrations (at higher amounts, consistent with previous studies [32] , we see poly-G having an inhibitory effect). Poly-G has been reported to interact with both the RING domain and the acid domain of Mdm2 [33] ; thus exactly how this ligand stabilizes or promotes acid domain interactions is unclear and will form the basis for further studies.
Although the physiological significance of an interaction between Mdm2 and IRF-2 has not been addressed by the present study, we have shown that these two proteins can be immunoprecipitated from cells in the same complex (Figure 1 ). In addition, we have preliminary results suggesting that the association between endogenous IRF-2 and Mdm2 can be up-regulated by dsRNA (double-stranded RNA), a viral mimetic that can stimulate an IFN response. As IRF-2 has been shown to prevent the overproduction of IFN-β by acting as a transcriptional repressor [34] , it is possible that Mdm2 may play an as yet undefined role in innate immunity. Thus it will be of interest to determine how Mdm2-mediated ubiquitination of IRF-2 impacts on its diverse functions in growth control and immunity [35, 36] .
In conclusion, the important feature of the present study is the ability to use bioinformatic screens to search for homologous linear interaction motifs derived from p53 with other proteins in the human proteome with the potential to serve as Mdm2 proteindocking sites. The use of IRF-2 as a substrate for ubiquitination reactions, especially in comparison with tetrameric p53, will provide us with an opportunity to develop deeper insights into the mechanism of E3-mediated substrate ubiquitination. The requirement for two docking sites in IRF-2 to sensitize the protein to Mdm2-mediated ubiquitination indicates, for example, that the dual-site docking mechanism that occurs on p53 is not related to the tetrameric structure of the protein. Instead, it is the structure of Mdm2 on a generic substrate with two docking sites that predisposes the protein to catalyse E2-mediated ubiquitin transfer. The analysis of other substrates in the human proteome with varying degrees of homology to the two Mdm2-docking sites identified in IRF-2 and p53 will also shed further light on the ubiquitin reaction mechanism as well as other physiological mechanisms of Mdm2 function in cells.
